Potential role of a selective retinoid receptor agonist bexarotene (LGD1069) in the treatment of advanced, metastatic NSCLC

被引：0

作者：

Dziewanowska, ZE ^{[1
]}

Negro-Vilar, A ^{[1
]}

Mabry, M ^{[1
]}

Hermann, T ^{[1
]}

Lamph, WW ^{[1
]}

Bissonnette, RP ^{[1
]}

Loewen, G ^{[1
]}

机构：

[1] Ligand Pharmaceut Inc, San Diego, CA USA

来源：

PROCEEDINGS OF THE 9TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE | 2004年

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：121 / 124

页数：4

共 12 条

[1]

BISSONNETTE R, 2004, P AM ASSOC CANC RES, V45, P1989

[2]

Brabender J, 2002, CLIN CANCER RES, V8, P438

[3]

DRAGNEV KH, 2004, P AN M AM SOC CLIN, P7356

[4]

EDELMAN MJ, 2004, P AN M AM SOC CLIN, P7104

[5]

FAN B, 2004, P AN M AM SOC CLIN, P7157

[6]

JACOBS CD, 2003, P AN M AM SOC CLIN, P2798

[7] Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer [J].

Khuri, FR ;

Rigas, JR ;

Figlin, RA ;

Gralla, RJ ;

Shin, DM ;

Munden, R ;

Fox, N ;

Huyghe, MR ;

Kean, Y ;

Reich, SD ;

Hong, WK .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2626-2637

[8]

Rizvi N, 2001, Clin Lung Cancer, V2, P210, DOI 10.3816/CLC.2001.n.005

[9]

RIZVI NA, 2002, P AN M AM SOC CLIN, P1334

[10]

YEN WC, 2004, P AM ASSOC CANC RES, V45, P2144

← 1 2 →